EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Inclisiran: a new generation of lipid-lowering siRNA therapeutic

Yanzhen Zhang, Huaigang Chen, Lang Hong, Hong Wang, Bin Li, Mengyin Zhang, Jiamei Li, Liu Yang, Fan Liu

Frontiers in Pharmacology · 13.10.2023 · 14

DOI: 10.3389/fphar.2023.1260921 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 13.10.2023. Verfasst von Yanzhen Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Shunyi Hospital, Beijing Traditional Chinese Medicine Hospital, Beijing, China. Die Arbeit wurde bisher 57-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atherosclerotic heart disease (AHD) is a major cause of morbidity and mortality worldwide. Lowering low-density lipoprotein cholesterol (LDL-C) levels is a key strategy to prevent and treat AHD. Inclisiran is a novel siRNA drug that targets proprotein convertase subtilisin/kexin type 9 (PCSK9) gene expression and reduces LDL-C levels with only two or three injections per year. This review summarizes the mechanism, efficacy, safety, and applications of Inclisiran in various populations and settings, based on recent literature. It also compares Inclisiran with other lipid-lowering drugs, especially other PCSK9 inhibitors. We conclude that Inclisiran is a promising lipid-lowering agent that can provide convenience and effectiveness for patients with high cardiovascular risk. However, some challenges and limitations remain for Inclisiran, such as its long-term safety and efficacy, its cost-effectiveness and accessibility, and its interactions and synergies with other drugs. These issues need further investigation and evaluation in future studies.

Schlagwörter

Stichwörter der Autor:innen

InclisiranPCSK9cardiovascular risklipid-lowering therapiessiRNA

Autor:innen und Institutionen

  • Department of Rheumatology, Shunyi Hospital, Beijing Traditional Chinese Medicine Hospital, Beijing, China.
  • Medical College of Nanchang University, Nanchang, China.
  • Department of Cardiology, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, China.
  • Pharmacy Department, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, China.
  • Laboratory Department, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, China.
  • Department of Hematology Jiangxi Hospital of Traditional Chinese Medicine, Nanchang, China.

Zitieren

APA

Zhang, Y., Chen, H., Hong, L., Wang, H., Li, B., Zhang, M., Li, J., Yang, L., & Liu, F. (2023). Inclisiran: a new generation of lipid-lowering siRNA therapeutic. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1260921

Vancouver

Zhang Y, Chen H, Hong L, Wang H, Li B, Zhang M, et al. Inclisiran: a new generation of lipid-lowering siRNA therapeutic. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1260921

BibTeX
@article{Zhang2023,
  author = {Zhang, Yanzhen and Chen, Huaigang and Hong, Lang and Wang, Hong and Li, Bin and Zhang, Mengyin and Li, Jiamei and Yang, Liu and Liu, Fan},
  title = {Inclisiran: a new generation of lipid-lowering siRNA therapeutic},
  journal = {Frontiers in Pharmacology},
  year = {2023},
  volume = {14},
  doi = {10.3389/fphar.2023.1260921}
}
Kostenlos starten →